R
Richard L. Schilsky
Researcher at University of Chicago
Publications - 187
Citations - 30184
Richard L. Schilsky is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Clinical trial. The author has an hindex of 50, co-authored 163 publications receiving 27855 citations.
Papers
More filters
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron,Donald A. Berry,Constance Cirrincione,Clifford A. Hudis,Eric P. Winer,William J. Gradishar,Nancy E. Davidson,Silvana Martino,Robert B. Livingston,James N. Ingle,Edith A. Perez,John T. Carpenter,David D. Hurd,James F. Holland,Barbara L. Smith,Carolyn I. Sartor,Eleanor H. Leung,Jeffrey S. Abrams,Richard L. Schilsky,Hyman B. Muss,Larry Norton +20 more
TL;DR: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
Journal ArticleDOI
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,Donald A. Berry,George D. Demetri,Constance Cirrincione,Lori J. Goldstein,Silvana Martino,James N. Ingle,M. Robert Cooper,Daniel F. Hayes,Katherine Tkaczuk,Gini F. Fleming,James F. Holland,David B. Duggan,John T. Carpenter,Emil Frei,Richard L. Schilsky,William C. Wood,Hyman B. Muss,Larry Norton +18 more
TL;DR: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Journal ArticleDOI
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra,Carmen J. Allegra,J. Milburn Jessup,Mark R. Somerfield,Stanley R. Hamilton,Elizabeth H. Hammond,Daniel F. Hayes,Pamela K. McAllister,Roscoe F. Morton,Richard L. Schilsky +9 more
TL;DR: This PCO addresses the utility of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy with cetuximab or panitumumab with a systematic review of the relevant literature.
Journal ArticleDOI
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler,Donna Niedzwiecki,Donna Hollis,Susan Sutherland,Deborah Schrag,Herbert Hurwitz,Federico Innocenti,Mary F. Mulcahy,Eileen M. O'Reilly,Timothy F. Wozniak,Joel Picus,Pankaj Bhargava,Robert J. Mayer,Richard L. Schilsky,Richard M. Goldberg +14 more
TL;DR: The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients, and the only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension and proteinuria.